BiotechTube
KaliVir Immunotherapeutics

KaliVir Immunotherapeutics

Pittsburgh, United States· Est.
kalivir.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $125M

Overview

KaliVir Immunotherapeutics is a private, Pittsburgh-based biotech founded in 2019, focused on engineering novel oncolytic viruses to treat cancer. Its proprietary VET platform aims to overcome limitations of earlier oncolytic viruses by enhancing tumor selectivity, immune activation, and the ability to deliver therapeutic payloads. The company has assembled a seasoned leadership team with deep experience in oncolytic virus development and has secured a significant partnership with Roche for its lead candidate, positioning it as a notable player in the next wave of cancer immunotherapy.

Oncology

Technology Platform

Vaccinia Enhanced Template (VET) platform: a next-generation oncolytic vaccinia virus engineered for enhanced tumor selectivity, immune activation, and capacity to be armed with therapeutic transgenes.

Funding History

3
Total raised:$125M
Series B$75M
Series A$42M
Seed$8M

Opportunities

The collaboration with Roche provides significant validation, resources, and a clear path for clinical development of VET3-TGI in combination with a leading checkpoint inhibitor.
The growing immuno-oncology market and demand for novel combination partners create a substantial opportunity for a successful next-generation oncolytic platform.

Risk Factors

High clinical development risk that its lead candidate may not demonstrate sufficient safety or efficacy.
Intense competition in the oncolytic virus and broader immuno-oncology space from larger, better-funded entities.
Execution and financing risks associated with being a private, pre-revenue company.

Competitive Landscape

KaliVir competes in the oncolytic virotherapy space against other biotechs like Turnstone Biologics, Replimune, and DNAtrix, as well as large pharma companies with OV programs. Its differentiation hinges on the specific engineering of its VET platform (potency, arming capacity) and the experience of its team in advancing vaccinia-based viruses.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →